BRAF and colorectal carcinoma: Although essential for immune responses, their mechanisms of action as immunotherapy targets are less direct and effective compared to IDO1.Thus, we further explored the role of IDO1 in the immunotherapy of BRAF V600E-mutant CRC and evaluated its feasibility as a promising immunotherapy target.